A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Latest Information Update: 01 Feb 2024
At a glance
- Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary)
- Indications Candidiasis; Haematological malignancies; Invasive bronchopulmonary aspergillosis; Mycoses; Zygomycosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma Global Development
- 24 May 2021 Results assessing the population pharmacokinetics, safety and tolerability of isavuconazonium sulfate when administered as IV or oral in pediatric patients, published in the Antimicrobial Agents and Chemotherapy.
- 30 Jul 2019 Status changed from active, no longer recruiting to completed.
- 24 Jun 2019 Status changed from recruiting to active, no longer recruiting.